1-3 of 3
D. Doss
Close
Sort by
Journal Articles

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

Paul G. Richardson, MD, S. Jagannath, MD, D.E. Avigan, MD, M. Alsina, R.L. Schlossman, MD, A. Mazumder, MD, N.C. Munshi, MD, I. Ghobrial, MD, D. Doss, MD, M.L. McKenney, NP, M.G. Farrell, BS, D.L. Warren, BS, L.E. Lunde, BA, B. Gourley, BA, S. Vaccaro, BS, C. Delaney, BSN, S. Pountney, BS, C.S. Mitsiades, MD, PhD, T. Hideshima, MD, PhD, C. Byrne, RN, R. Knight, MD, A. Birner, Pharm D, T. Myers, MD, E. Weller, PhD, K.C. Anderson, MD
Journal: Blood
Blood (2006) 108 (11): 405.
https://doi.org/10.1182/blood.V108.11.405.405
Published: 2006
Journal Articles

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

Paul Richardson, A. Chanan-Khan, R. Schlossman, N. Munshi, P. Wen, H. Briemberg, D. Kuter, A. Oaklander, S. Lonial, H. Hassoun, D. Doss, L. Lunde, S. Hayes, M. McKenney, K. Hande, L. Lai, A. Freeman, K. Dinand, C. McAlister, D. Warren, D. Collins, D. Esseltine, A. Amato, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 2548.
https://doi.org/10.1182/blood.V106.11.2548.2548
Published: 2005
Journal Articles

A Phase 1 Trial of Lenalidomide (REVLIMID ® ) with Bortezomib (VELCADE ® ) in Relapsed and Refractory Multiple Myeloma.

Paul Richardson, R. Schlossman, N. Munshi, D. Avigan, S. Jagannath, M. Alsina, D. Doss, M. McKenney, K. Hande, M. Farrell, S. Gorelik, K. Colson, D. Warren, L. Lunde, R. Michelle, G. Cole, C. Mitsiades, T. Hideshima, T. Myers, R. Knight, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 365.
https://doi.org/10.1182/blood.V106.11.365.365
Published: 2005